Announcements Trials
Browse Landscape

Phase

Phase 2 5

Status

Completed 31Recruiting 17Terminated 7Not yet recruiting 7Unknown 5Active not recruiting 5Withdrawn 4Suspended 1No longer available 1

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 5Observational 2

Sponsor

Cancer Type

Breast 3Gastrointestinal 2Thoracic 1Head & Neck 1Gynecologic 1CNS 1

Conditions

Uterine Cervical Neoplasms 1Salivary Gland Neoplasms 1Rare Tumour 1HER2-positive Breast Cancer 1Cholangiocarcinoma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1Breast Cancer With Brain Metastasis 1Brain Neoplasms 1

Interventions

Cisplatin 122Carboplatin 121Drug Therapy 118Bevacizumab 105Capecitabine 99Oxaliplatin 97Radiotherapy 95Paclitaxel 88Gemcitabine 88tislelizumab 87Cyclophosphamide 86Specimen Handling 80pembrolizumab 76toripalimab 67Magnetic Resonance Spectroscopy 65Fluorouracil 62sintilimab 59Injections 57Surgical Procedures, Operative 56Docetaxel 54anlotinib 51130-nm albumin-bound paclitaxel 48Immune Checkpoint Inhibitors 47fludarabine 46Standard of Care 45Pemetrexed 43Blood Specimen Collection 43Biopsy 43venetoclax 41lenvatinib 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Not yet recruiting × neratinib × Clear all
NCT07152782 2025-09-03

THUNDER

Fudan University

Phase 2 Not yet recruiting
202 enrolled
Breast

Breast Cancer With Brain Metastasis

NCT07019272 2025-06-13

Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study

Hebei Medical University Fourth Hospital

Not yet recruiting
170 enrolled
Breast

HER2-positive Breast Cancer

NCT06813079 2025-02-18

Using Tumor Models to Determine Treatments

University Health Network, Toronto

Phase 2 Not yet recruiting
25 enrolled
Gastrointestinal

Carcinoma, Carcinoma, Pancreatic Ductal

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting
200 enrolled

Rare Tumour

NCT06519110 2024-07-25

CVL009-C2001

Convalife (Shanghai) Co., Ltd.

Phase 2 Not yet recruiting
60 enrolled
GastrointestinalGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Salivary Gland Neoplasms, Cholangiocarcinoma

NCT06374888 2024-04-19

Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases

Convalife (Shanghai) Co., Ltd.

Phase 2 Not yet recruiting
28 enrolled
CNS

Brain Neoplasms

NCT05491057 2022-08-08

Treatment Patterns of Neratinib in HER2+ EBC in China

Pierre Fabre Medicament

Not yet recruiting
500 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡